James Smith

James Smith

Auto-generated profile, based on publicly available information

James Smith

UCL Great Ormond Street Institute of Child Health, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Disease in Children, London, WC1N 1DZ, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2012 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
YSYichen Shi
Yichen Shi
PKPeter Kirwan
Peter Kirwan
JSJames Smith
James Smith
HRHugh P C Robinson
Hugh P C Robinson
FLFrederick J Livesey
Frederick J Livesey

23 October 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
BCBradley S. Cobb
Bradley S. Cobb
AHArnulf Hertweck
Arnulf Hertweck
JSJames Smith
James Smith
EOEric O'COnnor
Eric O'COnnor
DGDaniel Graf
Daniel Graf
MMMatthias Merkenschlager
Matthias Merkenschlager
Micro RNAs (miRNAs) regulate gene expression at the posttranscriptional level. Here we show that regulatory T (T reg) cells have a miRNA profile distinct from conventional CD4 T cells. A partial T reg cell–like miRNA profile is conferred by the enforced expression of Foxp3 and, surprisingly, by the activation of conventional CD4 T cells. Depleting miRNAs by eliminating Dicer, the RNAse III enzyme that generates functional miRNAs, reduces T reg cell numbers and results in immune pathology. Dicer facilitates, in a cell-autonomous fashion, the development of T reg cells in the thymus and the efficient induction of Foxp3 by transforming growth factor β. These results suggest that T reg cell development involves Dicer-generated RNAs.

23 August 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Joao PereiraJoao Pereira
Joao Pereira
SSStephen N. Sansom
Stephen N. Sansom
JSJames Smith
James Smith
MDMarc-Werner Dobenecker
Marc-Werner Dobenecker
ATAlexander Tarakhovsky
Alexander Tarakhovsky
FLFrederick J. Livesey
Frederick J. Livesey
Multipotent progenitor cells of the cerebral cortex balance self-renewal and differentiation to produce complex neural lineages in a fixed temporal order in a cell-autonomous manner. We studied the role of the polycomb epigenetic system, a chromatin-based repressive mechanism, in controlling cortical progenitor cell self-renewal and differentiation. We found that the histone methyltransferase of polycomb repressive complex 2 (PCR2), enhancer of Zeste homolog 2 (Ezh2), is essential for controlling the rate at which development progresses within cortical progenitor cell lineages. Loss of function of Ezh2 removes the repressive mark of trimethylated histone H3 at lysine 27 (H3K27me3) in cortical progenitor cells and also prevents its establishment in postmitotic neurons. Removal of this repressive chromatin modification results in marked up-regulation in gene expression, the consequence of which is a shift in the balance between self-renewal and differentiation toward differentiation, both directly to neurons and indirectly via basal progenitor cell genesis. Although the temporal order of neurogenesis and gliogenesis are broadly conserved under these conditions, the timing of neurogenesis, the relative numbers of different cell types, and the switch to gliogenesis are all altered, narrowing the neurogenic period for progenitor cells and reducing their neuronal output. As a consequence, the timing of cortical development is altered significantly after loss of PRC2 function.

12 June 2009 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SSStephen N Sansom
Stephen N Sansom
DGDean S Griffiths
Dean S Griffiths
AFAndrea Faedo
Andrea Faedo
DKDirk-Jan Kleinjan
Dirk-Jan Kleinjan
YRYoulin Ruan
Youlin Ruan
FLFrederick J Livesey
Frederick J Livesey
Neural stem cell self-renewal, neurogenesis, and cell fate determination are processes that control the generation of specific classes of neurons at the correct place and time. The transcription factor Pax6 is essential for neural stem cell proliferation, multipotency, and neurogenesis in many regions of the central nervous system, including the cerebral cortex. We used Pax6 as an entry point to define the cellular networks controlling neural stem cell self-renewal and neurogenesis in stem cells of the developing mouse cerebral cortex. We identified the genomic binding locations of Pax6 in neocortical stem cells during normal development and ascertained the functional significance of genes that we found to be regulated by Pax6, finding that Pax6 positively and directly regulates cohorts of genes that promote neural stem cell self-renewal, basal progenitor cell genesis, and neurogenesis. Notably, we defined a core network regulating neocortical stem cell decision-making in which Pax6 interacts with three other regulators of neurogenesis, Neurog2, Ascl1, and Hes1. Analyses of the biological function of Pax6 in neural stem cells through phenotypic analyses of Pax6 gain- and loss-of-function mutant cortices demonstrated that the Pax6-regulated networks operating in neural stem cells are highly dosage sensitive. Increasing Pax6 levels drives the system towards neurogenesis and basal progenitor cell genesis by increasing expression of a cohort of basal progenitor cell determinants, including the key transcription factor Eomes/Tbr2, and thus towards neurogenesis at the expense of self-renewal. Removing Pax6 reduces cortical stem cell self-renewal by decreasing expression of key cell cycle regulators, resulting in excess early neurogenesis. We find that the relative levels of Pax6, Hes1, and Neurog2 are key determinants of a dynamic network that controls whether neural stem cells self-renew, generate cortical neurons, or generate basal progenitor cells, a mechanism that has marked parallels with the transcriptional control of embryonic stem cell self-renewal. Neural stem cells make all of the neurons in the brain. A key feature of these cells is the ability to regulate the balance between making more neural stem cells, the process of self-renewal, and making nerve cells, the process of neurogenesis. Too much self-renewal would result in a brain with too few neurons and abnormal circuitry; too much neurogenesis would deplete all of the neural stem cells too quickly, resulting in a small brain and neurological abnormalities. Little is currently known of the how neural stem cells control this fundamental choice. We used one transcription factor, Pax6, which is important for this decision, as an entry point to define the cellular networks controlling neural stem cell self-renewal and neurogenesis in the developing mouse brain. We found that the relative amount of Pax6 controls the balance between self-renewal and neurogenesis in neural stem cells. Increasing Pax6 levels drives the system towards neurogenesis, at the expense of self-renewal, by turning on a genetic programme for making neurons, whereas decreasing Pax6 turns off the genetic programme for neural stem cell self-renewal. In both cases, altering the levels of Pax6 ultimately leads to a small brain, but through very different mechanisms.

7 March 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YSYichen Shi
Yichen Shi
PKPeter Kirwan
Peter Kirwan
JSJames Smith
James Smith
GMGlenn MacLean
Glenn MacLean
SOStuart H. Orkin
Stuart H. Orkin
FLFrederick J. Livesey
Frederick J. Livesey
Cultured cerebral cortex neurons generated from human Down syndrome induced pluripotent stem cells rapidly develop Alzheimer’s disease pathologies.

1 March 2018 in Cell Reports
Verified
Journal Article
Open access
LELewis D. Evans
Lewis D. Evans
TWThomas Wassmer
Thomas Wassmer
GFGraham Fraser
Graham Fraser
JSJames Smith
James Smith
MPMichael Perkinton
Michael Perkinton
FLFrederick J. Livesey
Frederick J. Livesey
In Alzheimer's disease, neurofibrillary tangle pathology appears to spread along neuronal connections, proposed to be mediated by the release and uptake of abnormal, disease-specific forms of microtubule-binding protein tau MAPT. It is currently unclear whether transfer of tau between neurons is a toxic gain-of-function process in dementia or reflects a constitutive biological process. We report two entry mechanisms for monomeric tau to human neurons: a rapid dynamin-dependent phase typical of endocytosis and a second, slower actin-dependent phase of macropinocytosis. Aggregated tau entry is independent of actin polymerization and largely dynamin dependent, consistent with endocytosis and distinct from macropinocytosis, the major route for aggregated tau entry reported for non-neuronal cells. Anti-tau antibodies abrogate monomeric tau entry into neurons, but less efficiently in the case of aggregated tau, where internalized tau carries antibody with it into neurons. These data suggest that tau entry to human neurons is a physiological process and not a disease-specific phenomenon.